tirzepatide egfr cut-off Renal Outcomes of GLP-1 Receptor Agonists and Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review | Diabetes Therapy Updates on New Therapies for

It seems irresponsible to assume that if we pull one level over here, it would not impact another lever over there

Theres no evidence from human clinical trials that NAC causes cancer

For a 10 mg lyophilized vial: At 2.5 mg/week: 4 weeks of doses (perfectly matches the 28-day stability window) At 5 mg/week: 2 weeks of doses (well within stability limits) For a 30 mg lyophilized vial: At 2.5 mg/week: 12 weeks of doses (far exceeds 28-day window, significant waste) At 5 mg/week: 6 weeks (exceeds window by 2 weeks) At 7.5 mg/week: 4 weeks (perfect alignment) At 10 mg/week: 3 weeks (fully within stability limits) The reconstitution volume you choose affects how easy it is to measure each dose but does not change these timelines

When excluding patients who had been diagnosed with diabetic retinopathy in the second sensitivity study, use of once-weekly semaglutide was still independently associated with a higher risk to develop NAION (adjusted HR 226, 95% CI 157 327) in a multivariable model adjusted as in the first sensitivity analysis